Lila offers an AI‑driven protein design platform combined with a high‑throughput discovery pipeline to create therapeutic proteins with optimized affinity, selectivity, and pharmacokinetics. The system leverages chemically synthesizable scaffolds, unnatural amino acids, and proprietary linker‑payload technology to enable high‑dose subcutaneous delivery and targeted radiotherapy constructs for biopharma developers.
Funding
Funding not disclosed
Founders
Product
Problem
Developing protein therapeutics with high affinity, selectivity, and favorable pharmacokinetics is time‑intensive and often limited by conventional design methods, leading to suboptimal efficacy, safety, and formulation challenges for both oncology and non‑oncology indications.
Solution
Lila applies an AI‑powered protein design engine combined with a high‑throughput discovery platform (LILADD™) to generate therapeutic candidates that exhibit enhanced target binding, minimal off‑target tissue interaction, and optimized pharmacokinetic profiles. The platform incorporates chemically synthesizable chemistries, unnatural amino acids, and proprietary linker‑payload technologies to produce robust proteins suitable for high‑dose subcutaneous delivery. By integrating computational design with experimental validation, Lila accelerates the creation of next‑generation protein therapeutics for solid‑tumor targeted radiotherapy and long‑acting injectables across multiple disease areas.
Target Audience
Primary customers are biopharmaceutical companies and research organizations developing oncology and non‑oncology protein therapeutics that require high affinity, selective binding and convenient dosing formats.
Features
- AI-driven design algorithm that predicts and optimizes affinity, selectivity, and developability of protein candidates
- Use of chemically synthesizable scaffolds and unnatural amino acids to expand molecular diversity
- Proprietary linker‑payload system enabling targeted radiotherapy constructs for solid tumors
- Tailored pharmacokinetic engineering for high‑dose, subcutaneous long‑acting injectable formulations
- High‑throughput experimental validation pipeline to rapidly confirm computational predictions